[go: up one dir, main page]

Butler et al., 2022 - Google Patents

Engineering a natural ligand-based CAR: directed evolution of the stress-receptor NKp30

Butler et al., 2022

View PDF
Document ID
16980158851826075926
Author
Butler S
Brog R
Chang C
Sentman C
Huang Y
Ackerman M
Publication year
Publication venue
Cancer Immunology, Immunotherapy

External Links

Snippet

Abstract B7H6, a stress-induced ligand which binds to the NK cell receptor NKp30, has recently emerged as a promising candidate for immunotherapy due to its tumor-specific expression on a broad array of human tumors. NKp30 can function as a chimeric antigen …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display

Similar Documents

Publication Publication Date Title
CN113667021B (en) Chimeric antigen receptor targeting B7H3 and its application
JP6590694B2 (en) Methods and compositions for regulators of eukaryotic cells
KR102758039B1 (en) Antibody or chimeric antigen receptor targeting Claudin 18.2
CN112566698A (en) T cell receptor and engineered cells expressing the same
Butler et al. Engineering a natural ligand-based CAR: directed evolution of the stress-receptor NKp30
Yeboah et al. LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation
Sasso et al. Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies
AU2018310452A1 (en) Reagents for expanding cells expressing recombinant receptors
KR20190046854A (en) Chimeric antigen receptors comprising a BCMA-specific fibronectin type III domain and uses thereof
ES2971659T3 (en) Procedure for the production of a T cell composition
JP2021520209A (en) Diagnostic Assay for Detecting Tumor Antigens in Cancer Patients
Sarén et al. Complementarity-determining region clustering may cause CAR-T cell dysfunction
JP2023165793A (en) Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof
CN113980138B (en) EphA2 chimeric antigen receptor and uses thereof
Hua et al. Development of unique cytotoxic chimeric antigen receptors based on human scFv targeting B7H6
CN112912387A (en) Immunotherapy targeting KRAS or HER2 antigens
Wang et al. Potent, selective CARs as potential T-cell therapeutics for HPV-positive cancers
CN104829725A (en) Construction and application of bispecific antibody CD133*CD3
Chen et al. Rational protein design yields a CD20 CAR with superior antitumor efficacy compared with CD19 CAR
CN111303286B (en) anti-CD19 fully human antibody or antibody fragment, chimeric antigen receptor thereof and application thereof
Fierle et al. A cell-based phenotypic library selection and screening approach for the de novo discovery of novel functional chimeric antigen receptors
Duan et al. CAR-T cells based on a TCR mimic nanobody targeting HPV16 E6 exhibit antitumor activity against cervical cancer
KR20230137948A (en) Bispecific chimeric antigen receptor binding to CD19 and CD22
JP2025512797A (en) Improved Chimeric Receptors
Lee et al. An engineered NKp46 antibody for construction of multi-specific NK cell engagers